DSCSA and EU FMD: Q2 2026 Status on Pharmaceutical Serialisation and Verification

How pharmaceutical serialisation and verification frameworks are performing as Q2 2026 begins — and the recall integration work that separates operationally mature manufacturers from those still running older execution modes.

The Q2 2026 Landscape

For pharmaceutical manufacturers, distributors, and dispensers operating across the US and EU, the first half of 2026 has been defined by a shift in the conversation about DSCSA and EU FMD. The April status check we published earlier in the year captured the transition from stabilisation to enforcement. Now, with several months of full-enforcement experience across the DSCSA trading partner network and the EU FMD framework entering its eighth operational year, the conversation has shifted again — from compliance to performance.

The Q2 2026 question is not whether manufacturers are compliant with the frameworks. It is whether they are using the framework data to its full operational potential — particularly for recall and field-action execution, where the precision made possible by mature serialisation infrastructure translates directly into faster response, lower scope, and better regulator relationships.

DSCSA: From Full Enforcement to Operational Performance Assessment

The DSCSA stabilisation period closed for most categories of trading partners before 2026. The first months of 2026 have accordingly been a period of enforcement in practice, with FDA increasingly treating DSCSA operational compliance as an expectation rather than an aspiration.

Several patterns have emerged in the H1 2026 enforcement picture.

Data quality exceptions are now a primary enforcement signal. During the stabilisation period, FDA exercised discretion on data quality issues that were operationally understood to be transitional. With full enforcement in force, the exception pipeline from trading partners' EPCIS data validation is being treated as a compliance signal rather than an operational teething issue. Manufacturers receiving consistent exception reports from downstream trading partners should treat those reports as the enforcement precursor they are.

Verification-on-demand response time is being tracked operationally. Several trading partners have reported more structured tracking of manufacturer response time to verification-on-demand requests, both for suspect product investigation and for saleable returns processing. Manufacturers whose verification operations are staffed for volume but not for latency are finding that the latency standard matters.

Recall and field-action precision is the area where the H1 picture is most visible. Manufacturers that have integrated their DSCSA infrastructure with their recall and field-action processes have executed Q1 and Q2 2026 recalls with materially narrower scope than the prior norm — targeting specific serialised packages and specific trading partners rather than broad lot-level categories. Regulators have noted the operational maturity of these executions positively. Manufacturers executing recalls in the older mode — broad lot scope, category-level trading-partner notification — are finding the contrast with mature peers increasingly visible.

EU FMD: Operational Maturity and the Alert Management Discipline

The EU FMD framework's operational maturity in 2026 means that the EMVS and national medicines verification systems are stable infrastructure processing millions of verification and decommissioning events daily. The H1 2026 picture for EU FMD is accordingly about the quality of the operational disciplines built on top of the infrastructure, rather than the infrastructure itself.

Alert management quality is the primary operational differentiator. The EMVS generates alerts for verification events that do not match manufacturer-supplied data. In the early years of operation, alert volume was often managed as a compliance overhead rather than an intelligence resource. Now, the manufacturers that have built structured alert management operations — with classification, triage, investigation, and resolution protocols — are systematically discovering data quality issues, supply chain anomalies, and potential falsification events faster and more reliably than those that treat alerts as noise.

FMD recall integration is now a standard of care. For manufacturers executing pharmaceutical recalls in the EU, the use of EMVS verification data to identify the specific dispensers that have received and processed serialised units of the affected product is now a standard against which recall executions are assessed. Manufacturers that cannot identify, at the level of specific verified dispense events, where affected product has reached are executing at a lower operational standard than what the infrastructure makes possible.

The post-market surveillance intersection is increasingly visible to regulators. National medicines regulatory authorities in several EU member states have, in H1 2026, explicitly referenced EMVS-derived data in their post-market surveillance activity — including in the context of recalls and field alerts. The practical implication is that manufacturers' FMD operational data is increasingly part of the evidence base regulators draw on when assessing the brand's post-market surveillance posture.

Where H1 2026 Has Surfaced the Gaps

For pharmaceutical manufacturers that have been operating both frameworks, the H1 2026 experience has surfaced three common gap patterns.

Gap 1: Recall scope determination remains broader than the infrastructure permits. The most common operational gap is that recall scope is still being determined by lot and NDC category rather than by serial number and trading-partner identity. The infrastructure makes serial-level scope determination possible; the recall operating procedures have not been updated to take advantage of it. Closing this gap requires process and procedure work, not additional infrastructure.

Gap 2: Alert management is reactive rather than proactive. The second common gap is that EMVS alert management is handled reactively — alerts are resolved when trading partners escalate them, rather than being systematically investigated as potential signals of supply chain or quality issues. Proactive alert management is an operational discipline, not a technology requirement.

Gap 3: Multinational coordination still runs as parallel independent streams. For manufacturers operating across both DSCSA and EU FMD jurisdictions, the recall coordination model commonly remains two independent execution streams — one drawing on DSCSA transaction data, one drawing on EMVS verification data — rather than a unified recall workflow that integrates both. The unified model is operationally superior for both precision and regulator relationship management.

A Q2 2026 Readiness Checklist

For pharmaceutical manufacturers operating across both frameworks:

• [ ] DSCSA data quality review — assess error and exception rates by trading partner; confirm systematic data quality issues are in active remediation.
• [ ] Verification-on-demand performance review — confirm staffing, service-level tracking, and escalation procedures for production verification requests.
• [ ] EMVS alert management maturity assessment — review classification, investigation, and resolution discipline; confirm proactive rather than reactive posture.
• [ ] Recall scope determination procedure update — confirm that recall operating procedures incorporate serial-level scope determination using DSCSA and EMVS data.
• [ ] Multinational recall coordination model review — confirm that the recall playbook integrates DSCSA and EMVS data streams into a single coordinated workflow.
• [ ] Trading-partner communication infrastructure — confirm that recall notification procedures take full advantage of trading-partner identity data available through both frameworks.

How Software Supports Mature Framework Operations

The role of recall management software in a mature DSCSA and EU FMD environment is specific and important. The serialisation and verification infrastructure lives in dedicated supply chain integrity systems. The recall management platform provides the workflow layer above those systems where recall and field-action execution happens, where the audit trail is held, and where regulator interactions are documented.

SuperRecall.ai monitors 44+ regulatory databases including FDA recall and enforcement reports, EMA centralised actions, member-state pharmaceutical regulator alerts, and complementary feeds. Its workflow supports structured incident management with role-based access control and a tamper-evident audit log. For manufacturers operating in the mature DSCSA and FMD environment, the platform is designed to act as the recall workflow system of record, integrating with the supply chain integrity systems where serialisation data lives. SuperRecall.ai's SOC 2 posture is currently Audit In Progress, and we are happy to discuss the current state with security and procurement teams that need to verify the picture.

Closing Note

DSCSA and EU FMD have been operational for long enough that the 2026 standard of care is measured in operational performance, not implementation progress. Manufacturers using the framework data to execute precise, coordinated, well-documented recalls are visibly ahead of those still running older execution modes. The H2 2026 priority for any manufacturer that has not yet closed the gaps described here is to close them — because the enforcement and regulatory relationship cost of the older mode will continue to rise through the rest of the year.

If your team would like to walk through how SuperRecall.ai supports recall and field-action execution in mature DSCSA and FMD environments, book a working session or contact sales@superrecall.ai. Our pharmaceutical recall management guide and April DSCSA/FMD status check are useful companion reading.